Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio

Basit Öğe Kaydı
dc.contributor.authorKaynar, Mehmet
dc.contributor.authorYildirim, Mehmet Erol
dc.contributor.authorGul, Murat
dc.contributor.authorKilic, Ozcan
dc.contributor.authorCeylan, Kadir
dc.contributor.authorGoktas, Serdar
dc.date.accessioned2020-03-26T19:01:05Z
dc.date.available2020-03-26T19:01:05Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBACKGROUND: The aim of the current study is to evaluate NLR and PLR inflammation markers in PCa and BPH. METHODS: Clinical and pathological data such as age, prostate volume, PSA, NLR, and PLR levels of 201 patients were retrospectively reviewed. Pathological sample results of these patients were categorized either as benign or malign. The benign group consisted of chronic prostatitis and BPH and the malign group of PCa. The PSA levels were divided into three categories as PSA: 0-4 ng/ml, PSA: 4-10 ng/ml, and 10 ng/ml and above. RESULTS: In the benign category, the mean PLR values for PSA: 0-4 ng/ml is 131.8 +/- 31.2, for PSA: 4-10 ng/ml 124.7 +/- 83.9 and 10 ng/ml and above 124 +/- 53 in chronic prostatitis group and in the BPH group for PSA: 4-10 ng/ml 120.3 +/- 45.1, for PSA: 4-10 ng/ml 126 +/- 54,2, and 10 ng/ml and above 191.4 +/- 176.1. In the malign category, the mean PLR values of PCa patients is for PSA: 0-4 ng/ml 122.8 +/- 43.8, for PSA: 4-10 ng/ml 123 +/- 43.8, and above 10 ng/ml 179.1 +/- 94. Related to the variables of age, NLR, and mean prostate volume, there were no statistically significant differences. Statistically significant differences were observed in the mean PLR values only if the PSA level was 10 ng/ml and above (p: 0.044) in the BPH and PCa groups. The correlation of the PCa Gleason score and PSA, NLR and PLR parameters in the malign category revealed no statistically significant differences (P > 0.05). CONCLUSION: Effective malign and benign differentiation of prostate pathologies based on noninvasive inflammation biomarkers such NLR and PLR necessitate clinical studies with larger patient series.en_US
dc.identifier.doi10.3233/CBM-150458en_US
dc.identifier.endpage323en_US
dc.identifier.issn1574-0153en_US
dc.identifier.issn1875-8592en_US
dc.identifier.issue3en_US
dc.identifier.pmid25586096en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage317en_US
dc.identifier.urihttps://dx.doi.org/10.3233/CBM-150458
dc.identifier.urihttps://hdl.handle.net/20.500.12395/31886
dc.identifier.volume15en_US
dc.identifier.wosWOS:000355954400012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherIOS PRESSen_US
dc.relation.ispartofCANCER BIOMARKERSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectBenign prostatic hyperplasiaen_US
dc.subjectprostate canceren_US
dc.subjectplatelet to lymphocyte ratioen_US
dc.titleBenign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratioen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu